What is SpectraWAVE?
Founded in 2017 and based in Bedford, Mass., SpectraWAVE is dedicated to enhancing patient outcomes for coronary artery disease through advanced optical and computational insights. The company's flagship HyperVue Imaging System integrates DeepOCT images and near-infrared spectroscopy (NIRS) within optimized cardiac catheterization lab workflows. This system aims to empower interventionalists with superior decision-making capabilities for percutaneous stent placement, addressing the significant challenge of adverse events in CAD patients. The HyperVue system is indicated for imaging coronary arteries in patients undergoing interventional procedures.
How much funding has SpectraWAVE raised?
SpectraWAVE has raised a total of $63.2M across 2 funding rounds:
Series A
$13.2M
Series B
$50M
Series A (2021): $13.2M with participation from Deerfield Communications Inc
Series B (2024): $50M led by Lumira Ventures, Johnson & Johnson Innovation, and Heartwork
Key Investors in SpectraWAVE
Lumira Ventures
Lumira Ventures is a leading Canadian life sciences venture capital firm with a specialization in healthcare innovation across various stages, including medical devices. Their investment in SpectraWAVE aligns with their focus on companies aiming to improve patient outcomes.
Johnson & Johnson Innovation
Johnson & Johnson Innovation is a global entity focused on advancing healthcare solutions through strategic partnerships. Their participation suggests an interest in novel medical technologies that can positively impact human health.
Heartwork
Heartwork Inc, known for designing modern workspace solutions, has invested in SpectraWAVE. While their primary domain is workspace design, their investment may indicate a diversified portfolio strategy or a belief in the broader impact of healthcare technology.
What's next for SpectraWAVE?
The recent Series B financing, characterized as a major strategic investment, positions SpectraWAVE for significant scaling and further development of its groundbreaking HyperVue Imaging System. This substantial capital infusion is expected to accelerate market penetration, enhance research and development efforts for future system enhancements, and potentially expand its reach within the cardiovascular medical device sector. The company's focus on improving outcomes for the millions affected by coronary artery disease suggests a strategic direction towards becoming a leader in interventional cardiology diagnostics.
See full SpectraWAVE company page
